Thomas Shrader, PhD, CFA, is a Managing Director and Healthcare Analyst at BTIG. He provides coverage of the biotechnology sector, with a focus on large and smidcap companies. Prior to BTIG, Mr. Shrader was the Vice President of Strategy and Communications at Intrexon Corporation. Previously, he was a Biotechnology Research Analyst at Stifel. Earlier in his career, Mr. Shrader was on the Biochemistry Faculty at the Albert Einstein College of Medicine. He earned a BA from The Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology.
Coverage Area
| Company | Ticker |
|---|---|
| Precision BioSciences, Inc. | DTIL |
| Biogen, Inc. | BIIB |
| Denali Therapeutics Inc. | DNLI |
| Esperion Therapeutics, Inc. | ESPR |
| Gritstone bio | GRTS |
| G1 Therapeutics, Inc. | GTHX |
| MEI Pharma, Inc. | MEIP |
| MacroGenics, Inc. | MGNX |
| Arcus Biosciences, Inc. | RCUS |
| Seagen Inc. | SGEN |
| Synlogic, Inc. | SYBX |
| Verona Pharma plc | VRNA |
| Voyager Therapeutics, Inc. | VYGR |
| Xencor, Inc. | XNCR |
| Cue Biopharma, Inc. | CUE |
| IMV, Inc. | IMV |
| Alector Inc. | ALEC |
| Stoke Therapeutics, Inc. | STOK |
| Mersana Therapeutics | MRSN |
| BridgeBio Pharma, Inc. | BBIO |
| Minerva Neurosciences, Inc. | NERV |
| Checkmate Pharmaceuticals | CMPI |
| INmune Bio Inc. | INMB |
| Aldeyra Therapeutics | ALDX |
| Silence Therapeutics | SLN |
| Replimune Group, Inc. | REPL |
| SQZ Biotechnologies Co | SQZ |
| BioAtla | BCAB |
| Nuvation Bio | NUVB |
| OncoSec Medical | ONCS |
| Pliant Therapeutics | PLRX |
| GX Acquisition Corp. | GXGX |
| Gain Therapeutics, Inc. | GANX |